NATCO PHARMA
|
|
BOM : 524816     NSE : NATCOPHARM     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Aug 30,2024 |
Price(EOD): ₹ 1,537.45
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 27,535.73 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
NATCO PHARMA | -1.7% | 13% | 69.7% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 6% | 62.4% |
CIPLA | 3.9% | 7.3% | 33.9% |
DR REDDYS LABORATORIES | 1.2% | 4.2% | 20.1% |
ZYDUS LIFESCIENCES | 1.8% | -9.5% | 80.1% |
DIVIS LABORATORIES | 3.2% | 3.5% | 37.8% |
FUNDAMENTAL ANALYSIS OF NATCO PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NATCO PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
16.83
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,636.50 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 4.7
P/B Calculated based on Book Value of Rs 5,853.10 Cr
[Latest Year - Mar2024 - Consolidated Results ] 6.52
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 4,220.90 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
85% -22% -20% |
SHARE PRICE MOMENTUM OF NATCO PHARMA
NATCO PHARMA vs SENSEX
DEBT OF NATCO PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0.03 0.09 0.06 0.06 |
0.03 0.09 0.06 0.06 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF NATCO PHARMA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF NATCO PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
27.55% 61.83% 68.26% 73.05% |
19.47% 52.42% 60.72% 59.05% |
QtrlyTrend |
8 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
NATCO PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 2.5% | 7.5% | 54.8% |
S&P BSE 500 | 1.3% | 1.2% | 39.5% |
S&P BSE ALLCAP | 1.2% | 1.2% | 40.7% |
S&P BSE 250 SMALLCAP | 1.1% | 1.2% | 53% |
S&P BSE 400 MIDSMALLCAP | 1.1% | 0.9% | 53.3% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY PHARMA | 3.1% | 7.8% | 52.8% |
NIFTY SMALLCAP 50 | 1.5% | 2.3% | 68.6% |
NIFTY 500 | 1.4% | 1.3% | 40.2% |
NIFTY500 MULTICAP 50:25:25 | 1.3% | 1.2% | 44.8% |
NIFTY FREE SMALL 100 | 1.2% | 0.5% | 62% |
You may also like the below Video Courses
FAQ about NATCO PHARMA
Is NATCO PHARMA good for long term investment?
As on Aug 30,2024, the Fundamentals of NATCO PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of NATCO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NATCO PHARMA UnderValued or OverValued?
As on Aug 30,2024, NATCO PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of NATCO PHARMA ?
As on Aug 30,2024, the Intrinsic Value of NATCO PHARMA is Rs. 1,912.30 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 832.38
Fair Value [Median EV / Sales Model] : Rs. 1,960.90
Fair Value [Median Price / Sales Model] : Rs. 1,912.30
Estimated Median Fair Value of NATCO PHARMA : Rs. 1,912.30
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.